Malaria, particularly in its severe forms, remains a global health and economic burden. It causes the deaths of more than 600,000 people every year – most of them African children under five.
Bayer eyes Nubeqa’s label expansion in prostate cancer following Phase III win
Bayer’s Nubeqa is approved by the US FDA as a treatment for metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), in combination
July 18, 2024